In the biotech space, two deals are coming soon. Cramer said OncoMed Pharmaceuticals has five cancer drugs in early stage testing, while Agios Pharmaceuticals is working on early stage treatments for both cancer and metabolic disorders. Both IPOs are attractive, but Cramer said he'd buy and hold some OncoMed, while selling Agios after the IPO. Then there's NRG Energy's ( NRG) upcoming spinoff of NRG Yield, its dividend vehicle that's expects to offer 6% after it comes public. Cramer said with high-yielding stocks still under fire he's not a buyer of this stock, but would use it as a gauge for how the market is viewing the dividend stocks going forward.